Retrospective Study of Efficacy and Safety of Lianhua Qingwen Granules Combined with Lopinavir/Ritonavir in the Treatment of COVID-19

doi:10.14009/j.issn.1672-2124.2021.02.013

您当前的位置：

首页 >

文章列表页 >

Retrospective Study of Efficacy and Safety of Lianhua Qingwen Granules Combined with Lopinavir/Ritonavir in the Treatment of COVID-19

更新时间：2022-10-08

- Retrospective Study of Efficacy and Safety of Lianhua Qingwen Granules Combined with Lopinavir/Ritonavir in the Treatment of COVID-19
- Vol. 21, Issue 2, Pages: 179-181(2021)
- 作者机构：
  
  安徽医科大学附属六安医院(六安市人民医院)药学部
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2021.02.013
  CLC： R563.1
- Published：2021，
扫描看全文
[1]夏一淼,王法财,沈炳香,聂松柳.连花清瘟颗粒联合洛匹那韦/利托那韦治疗新型冠状病毒肺炎的疗效与安全性回顾性研究[J].中国医院用药评价与分析,2021,21(02):179-181+184.

Retrospective Study of Efficacy and Safety of Lianhua Qingwen Granules Combined with Lopinavir/Ritonavir in the Treatment of COVID-19. [J]. 21(2):179-181(2021)
[1]夏一淼,王法财,沈炳香,聂松柳.连花清瘟颗粒联合洛匹那韦/利托那韦治疗新型冠状病毒肺炎的疗效与安全性回顾性研究[J].中国医院用药评价与分析,2021,21(02):179-181+184. DOI： 10.14009/j.issn.1672-2124.2021.02.013.

Retrospective Study of Efficacy and Safety of Lianhua Qingwen Granules Combined with Lopinavir/Ritonavir in the Treatment of COVID-19. [J]. 21(2):179-181(2021) DOI： 10.14009/j.issn.1672-2124.2021.02.013.

摘要

目的:探讨连花清瘟颗粒联合洛匹那韦/利托那韦治疗新型冠状病毒肺炎（COVID-19）的疗效与安全性。方法:回顾性选取截至2020年3月24日安徽医科大学附属六安医院收治的50例住院期间应用连花清瘟颗粒联合洛匹那韦/利托那韦片治疗的COVID-19患者资料

总结和分析治疗前后临床症状、影像学检查和实验室检查的变化及不良反应发生情况。结果:50例患者经连花清瘟颗粒联合洛匹那韦/利托那韦治疗后的临床症状较治疗前明显改善。肺部影像学检查结果显示

平均改善时间为（10.83±5.91） d。经7 d治疗后

实验室检查各项指标（包括白细胞、淋巴细胞、丙氨酸转氨酶、天冬氨酸氨基转移酶、肌酸激酶、乳酸脱氢酶及C反应蛋白等）正常患者数均较治疗前增加

其中C反应蛋白水平的改善情况最为明显。50例患者中

发生不良反应24例

多为轻症

对症治疗后均缓解。结论:在COVID-19尚无特效治疗药物的情况下

连花清瘟颗粒联合洛匹那韦/利托那韦治疗方案可供临床治疗经验性选择

在用药过程中需密切关注不良反应

保障用药安全。

Abstract

OBJECTIVE: To probe into the efficacy and safety of Lianhua Qingwen granules combined with lopinavir/ritonavir in the treatment of COVID-19. METHODS: Clinical data of 50 patients with COVID-19 who were treated with Lianhua Qingwen granules combined with lopinavir/ritonavir tablets were retrospectively selected until Mar. 24

2020 in Lu’an Hospital Affiliated to Anhui Medical University. Changes of clinical symptoms

imaging examination and laboratory examination before and after treatment and incidence of adverse drug reactions were summarized and analyzed. RESULTS: The clinical symptoms of 50 patients were significantly improved after treatment with Lianhua Qingwen granules combined with lopinavir/ritonavir. The results of lung imaging examination showed that the average improvement time was（ 10. 83 ± 5. 91） d. After 7 d of treatment

the number of patients with normal indicators（ including white blood cells

lymphocytes

alanine aminotransferase

aspartic acid aminotransferase

creatine kinase

lactate dehydrogenase and C-reactive protein） increased compared with those before treatment

and the improvement of C-reactive protein level was the most significant. Adverse drug reactions occurred in 24 of the 50 patients

most of which were mild and all resolved after symptomatic treatment. CONCLUSIONS: In the absence of specific therapeutic drugs for COVID-19

Lianhua Qingwen granules combined with lopinavir/ritonavir can be used as an empirical choice for clinical treatment. Adverse drug reactions should be closely monitored during the medication process to ensure the medication safety.

关键词

连花清瘟颗粒洛匹那韦/利托那韦新型冠状病毒肺炎疗效安全性

Keywords

Lianhua Qingwen granulesLopinavir/ritonavirCOVID-19EfficacySafety

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and Safety of Apatinib Mesylate Combined with Etoposide in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer

Correlation Between Dose Exposure Intensity and Efficacy and Safety of Apatinib in the Treatment of Advanced Gastric Cancer

Xiaoer Xiaoshi Granules Combined with Saccharomyces Boulardii in the Treatment of Functional Dyspepsia in Children

Efficacy of Carrelizumab Combined with Amlotinib in the Treatment of Advanced Gastric Cancer and Its Effect on Short-Term Prognosis

Efficacy of Oseltamivir Phosphate Capsules Combined with Lianhua Qingwen Granules in the Treatment of Influenza A H1N1

Related Author

WU Yanfang

CHEN Lei

MA Xiao

WANG Jingting

MA Zhongjun

WANG Jing

CAO Bangwei

CHEN Lin

Related Institution

Dept. of Gynaecology and Obstetrics,the Sixth Medical Center of PLA General Hospital

Cancer Center, Beijing Friendship Hospital, Capital Medical University

Dept.of Pharmacy, Haikou Hospital Affiliated to Xiangya Medical College of Central South University

Dept.of Pediatrics, Haikou Hospital Affiliated to Xiangya Medical College of Central South University

Dept.of Oncology and Hematology,Nanchuan People’s Hospital,Chongqing Medical University

⁰